See more : Strata Investment Holdings Plc (SRT.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Talaris Therapeutics, Inc. (TALS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Talaris Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Jianpu Technology Inc. (AIJTY) Income Statement Analysis – Financial Results
- Zhongman Petroleum and Natural Gas Group Corp., Ltd. (603619.SS) Income Statement Analysis – Financial Results
- Medgold Resources Corp. (MGLDF) Income Statement Analysis – Financial Results
- Hotel Shilla Co.,Ltd (008775.KS) Income Statement Analysis – Financial Results
- Yoong Onn Corporation Berhad (5159.KL) Income Statement Analysis – Financial Results
Talaris Therapeutics, Inc. (TALS)
About Talaris Therapeutics, Inc.
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 57.01M | 34.25M | 15.28M | 13.37M |
| General & Administrative | 19.47M | 13.26M | 7.41M | 5.01M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.47M | 13.26M | 7.41M | 5.01M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 76.48M | 47.51M | 22.68M | 18.38M |
| Cost & Expenses | 76.48M | 47.51M | 22.68M | 18.38M |
| Interest Income | 900.00 | 0.00 | 400.00 | 200.00 |
| Interest Expense | 2.58M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.16M | 623.00K | 447.00K | 379.00K |
| EBITDA | -74.32M | -46.88M | -22.24M | -18.00M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -76.48M | -47.51M | -22.68M | -18.38M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.58M | -326.00K | -23.00K | 223.00K |
| Income Before Tax | -73.89M | -47.83M | -22.71M | -18.16M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.17M | 326.00K | 23.00K | -223.00K |
| Net Income | -68.73M | -48.16M | -22.73M | -17.93M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.66 | -16.53 | -34.00 | -28.09 |
| EPS Diluted | -16.66 | -16.53 | -34.00 | -28.09 |
| Weighted Avg Shares Out | 4.12M | 2.91M | 668.51K | 638.33K |
| Weighted Avg Shares Out (Dil) | 4.12M | 2.91M | 668.51K | 638.33K |
bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases
Cellectis Patent Encompassing Broad Uses of Gene Editing Technologies Maintained by USPTO
Calyxt Patent Encompassing Broad Uses of Plant Gene Editing Technologies Maintained by USPTO
Thermo Fisher Scientific CRISPR-Cas9 Genome Editing Tools Named Top Innovations of 2016
Life Technologies Releases CRISPR Products for Simple, Rapid Gene Editing
Source: https://incomestatements.info
Category: Stock Reports